Aptorum's DiamiR Acquisition: Liquid Biopsies Poised to Reshape Alzheimer's Diagnosis

NEW YORK, NY – November 19, 2025

Aptorum Group Ltd. is making a significant bet on the future of Alzheimer’s disease diagnostics with its planned acquisition of DiamiR Biosciences. The deal, expected to close in Q1 2026, positions Aptorum to capitalize on the burgeoning market for non-invasive, blood-based tests for early detection and monitoring of the debilitating neurodegenerative disease. While the financial terms remain undisclosed, the move highlights a growing industry trend – a shift away from costly and invasive diagnostic procedures towards more accessible and scalable liquid biopsies.

The Promise of Liquid Biopsies for Alzheimer's

For decades, diagnosing Alzheimer’s disease has relied on a combination of cognitive assessments, brain imaging – often PET scans – and, in some cases, cerebrospinal fluid analysis. These methods are not only expensive but also carry risks and can be challenging for patients to access. DiamiR’s core technology focuses on analyzing microRNA (miRNA) signatures in plasma, offering a potentially revolutionary approach. MicroRNAs are small, non-coding RNA molecules that play a crucial role in gene expression. Their presence and concentration in blood can serve as indicators of neurological changes associated with Alzheimer's, even before symptoms manifest.

“The ability to detect these biomarkers in a simple blood test has the potential to drastically change the landscape of Alzheimer’s diagnosis,” explains one industry analyst. “Current methods are often reserved for those already exhibiting symptoms, hindering the possibility of early intervention.” The company's research, conducted in collaboration with leading institutions like NYU and UPenn Alzheimer's Disease Research Centers, aims to classify and monitor stages of neurodegeneration with increased accuracy and speed. Research suggests that DiamiR’s methods offer the potential for significantly improved patient stratification and personalized treatment strategies.

Aptorum’s Strategic Move & Market Landscape

Aptorum, currently focused on oncology and infectious diseases, sees DiamiR as a strategic addition to its portfolio. The acquisition allows the company to diversify its revenue streams and enter a rapidly expanding market. The global Alzheimer's disease diagnostics market is projected to reach over $25 billion by 2034, driven by the aging global population and increasing prevalence of the disease. While several companies, including C2N Diagnostics, Roche, and Mayo Clinic, are developing blood-based tests, DiamiR’s focus on miRNA biomarkers positions it as a unique player.

“This isn’t just about offering another diagnostic test,” says a source close to Aptorum. “It's about building a comprehensive platform for early disease detection and potentially even preventative care.” However, the landscape is becoming increasingly crowded. Competitors are actively exploring various biomarkers, including amyloid and tau proteins, further intensifying the competition. Aptorum’s ability to successfully integrate DiamiR’s technology and navigate the regulatory hurdles will be critical to its success. The company’s financial stability, assessed through SEC filings and investor reports, will also play a vital role in supporting this ambitious venture.

Intellectual Property & Validation of Technology

DiamiR Biosciences boasts a robust intellectual property portfolio, with over 50 issued patents covering methods for detecting neurodegenerative diseases using miRNA signatures. These patents are crucial for protecting its technology and establishing a competitive advantage. The patents also cover methods for identifying specific miRNA profiles associated with different stages of Alzheimer’s and other dementias. This provides a potential pathway for developing personalized diagnostics and monitoring treatment responses.

The upcoming presentation of research at the Clinical Trials on Alzheimer’s Disease (CTAD) 2025 conference, funded by a National Institute on Aging SBIR grant, is a key validation step for DiamiR’s technology. Presenting data at such a prestigious conference will enhance the company's credibility and attract further investment. While details of the research are still under wraps, the collaboration with leading academic institutions like NYU and UPenn suggests promising results. Experts are optimistic that the data will demonstrate the accuracy and reliability of DiamiR’s miRNA-based diagnostic approach.